N. Manamley

Outcomes in patients with chronic kidney disease not on dialysis receiving extended dosing regimens of darbepoetin alfa: long-term results of the EXTEND observational cohort study

A. Guérin, C. Winearls, M. Suranyi, 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Darbepoetin alfa once monthly corrects anaemia in patients with chronic kidney disease not on dialysis

Mark E. Thomas, M. Fung, S. Roger, 2014, Nephrology.

Serum phosphorus reduction in dialysis patients treated with cinacalcet for secondary hyperparathyroidism results mainly from parathyroid hormone reduction

M. Vervloet, D. Fouque, P. Ureña, 2013, Clinical kidney journal.

Preservation of Anemia Control and Weekly ESA Dosage After Conversion from PEG-Epoetin Beta to Darbepoetin Alfa in Adult Hemodialysis Patients: The TRANSFORM Study

J. Chanliau, J. Addison, M. Farouk, 2014, Advances in Therapy.

Safety and usage of darbepoetin alfa in children with chronic kidney disease: prospective registry study

B. Hoppe, F. Schaefer, L. Pape, 2015, Pediatric Nephrology.

Cinacalcet for secondary hyperparathyroidism: from improved mineral levels to improved mortality?

M. Vervloet, L. Reichert, P. S. Smak Gregoor, 2013, The Netherlands journal of medicine.

Dose Conversion Ratio in Hemodialysis Patients Switched from Darbepoetin Alfa to PEG-Epoetin Beta: AFFIRM Study

J. Addison, M. Farouk, N. Manamley, 2013, Advances in Therapy.

AMG 151 (ARRY‐403), a novel glucokinase activator, decreases fasting and postprandial glycaemia in patients with type 2 diabetes

S. Mudaliar, P. Raskin, J. Sierra-johnson, 2016, Diabetes, obesity & metabolism.

Data sharing and the evolving role of statisticians

A. Scrimgeour, M. Sydes, H. Burger, 2016, BMC Medical Research Methodology.